Drug for Non-Obstructive HCM Moves Along

 

Heart Metabolics announced today that its drug, Perhexiline, has moved into Phase 2b trials. The drug is intended for those patients with HCM and moderate to severe heart failure with preserved left ventricular function. Results of the Phase 2a study found the drug improved exercise capacity and quality of life in patients taking the drug.

To learn more about the staging of clinical drug trials and how they work, click here.